MDWD · CIK 0001593984
What MediWound Ltd. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for MDWD. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- single manufacturing site — Yavne, Israelhigh
All near-term revenue depends on products from one manufacturing site in Yavne, Israel (the expanded NexoBrid facility); a shutdown or force majeure — in a country at war — would halt all production with limited inventory cover.
“We currently rely on a single manufacturing site in Yavne, Israel, and we expect that all of our revenues in the near future will be derived from products manufactured at this site.”
Supplier concentration
- bromelain SP — single supplier (CBC) with facilities in Taiwanmedium
The key starting material for every product (NexoBrid, EscharEx, pipeline) comes from one supplier, Challenge Bioproducts Corporation, whose proprietary manufacturing sits in Taiwan — a sole-source dependence stacked on Taiwan geopolitical risk.
“We currently procure bromelain SP, a key substance starting material in the manufacturing of NexoBrid, EscharEx and our pipeline product candidates, from a single supplier, Challenge Bioproducts Corporation Ltd. ("CBC").”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“After the Initial Term and optional two-year extension, Vericel, at its sole discretion, may choose to extend the Supply Agreement's term for additional one-year period for a potential total term of fifteen years.”
Cited →“we entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.”
Cited →
Its suppliers
Challenge Bioproducts Corporation Ltd. (CBC, Taiwan)
“We currently procure bromelain SP, a key substance starting material in the manufacturing of NexoBrid, EscharEx and our pipeline product candidates, from a single supplier, Challenge Bioproducts Corporation Ltd. ("CBC").”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch